Terrapeutics Pharma · raw details

Terrapeutics focuses on discovering novel therapeutic solutions from soil-based microorganisms. Its groundbreaking discovery platform AIM-N (pronounced "AMEN" - Activated Induction of Metabolites in Nature) unlocks soil's full potential and discovers novel small molecules that can target 'undruggable' targets, mainly Protein-Protein Interactions (PPIs). It does that by disrupting a natural soil environment with an engineered microorganism (according to the predefined drug target) that threatens it. This threat forces its residents to respond by producing small molecules against the drug target we are aiming at. The results show that this technology identifies the specific drug-producing bacteria and the genes associated with such activity with high success rates.

The company's lead discovery program focuses on pan KRAS inhibitors, the next generation of solutions for a target that drives 25% of cancers. Through the KRAS discovery program, the company has demonstrated its ability to overcome two critical bottlenecks in soil-based drug discovery: swiftly identifying drug-producing bacteria and their associated biosynthetic gene clusters against a predefined drug target, even when it is challenging.

Recent Progress: • Discovered and isolated the first natural pan-KRAS inhibiting molecules from soil bacteria; the second and third discoveries are in their final confirmation stages. • 1st hit compound TRP-001 demonstrates significant potency and superiority over competing molecules that are either commercial or in advanced clinical development • Developed our next-generation platform that becomes a plug-and-play discovery technology for PPI inhibitors.

We're currently backed by Peregrine Ventures, Bristol Myers Squibb, Illumina, and others. This year, we're entering a $10M seed round to expand our platform and accelerate multiple discovery programs targeting pharmaceutical research's most challenging "holy grail" targets.